- All sections
- C - Chemistrymetallurgy
- C07D - Heterocyclic compounds
- C07D 471/10 - Spiro-condensed systems
Patent holdings for IPC class C07D 471/10
Total number of patents in this class: 2518
10-year publication summary
|
145
|
170
|
174
|
176
|
195
|
222
|
230
|
215
|
198
|
141
|
| 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
Principal owners for this class
| Owner |
All patents
|
This class
|
|---|---|---|
| Bristol-myers Squibb Company | 4757 |
59 |
| Merck Sharp & Dohme LLC | 3737 |
53 |
| Novartis AG | 10173 |
50 |
| F. Hoffmann-La Roche AG | 7808 |
49 |
| Merck Patent GmbH | 5735 |
44 |
| Hoffmann-La Roche Inc. | 3818 |
39 |
| Pfizer Inc. | 3409 |
36 |
| Boehringer Ingelheim International GmbH | 4486 |
34 |
| Janssen Pharmaceutica N.V. | 3160 |
25 |
| Arvinas Operations, Inc. | 263 |
23 |
| Incyte Corporation | 1066 |
22 |
| The Regents of the University of Michigan | 5016 |
21 |
| Astellas Pharma Inc. | 1039 |
21 |
| Merck Sharp & Dohme Corp. | 2183 |
20 |
| Syngenta Participations AG | 1495 |
20 |
| H. Lundbeck A/S | 1233 |
20 |
| Nurix Therapeutics, Inc. | 116 |
20 |
| Takeda Pharmaceutical Company Limited | 2700 |
19 |
| Amgen Inc. | 4440 |
18 |
| Celgene Quanticel Research, Inc. | 154 |
18 |
| Other owners | 1907 |